SE9402332D0 - IGF-1 - Google Patents

IGF-1

Info

Publication number
SE9402332D0
SE9402332D0 SE9402332A SE9402332A SE9402332D0 SE 9402332 D0 SE9402332 D0 SE 9402332D0 SE 9402332 A SE9402332 A SE 9402332A SE 9402332 A SE9402332 A SE 9402332A SE 9402332 D0 SE9402332 D0 SE 9402332D0
Authority
SE
Sweden
Prior art keywords
igf
glycosylated
relates
truncated
amino acid
Prior art date
Application number
SE9402332A
Other languages
Swedish (sv)
Inventor
Rolf Eriksson
Stig Johansson
Harriet Roennholm
Anna Skottner
Karin Sonesson
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9402332A priority Critical patent/SE9402332D0/en
Publication of SE9402332D0 publication Critical patent/SE9402332D0/en
Priority to IL11427095A priority patent/IL114270A0/en
Priority to CA002193399A priority patent/CA2193399A1/en
Priority to EP95925201A priority patent/EP0769022A1/en
Priority to AU29406/95A priority patent/AU2940695A/en
Priority to PCT/SE1995/000774 priority patent/WO1996001275A1/en
Priority to JP8503823A priority patent/JPH10502623A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to O-glycosylated authentic IGF-I, having three or more mannose residues to the Ser69 amino acid of the IGF-polypeptide chain or being truncated and having two mannose residues to the Thr29 amino acid of the truncated IGF-polypeptide chain. The O-glycosylated IGF-I according to the invention have substantially no insulin receptor affinity, which makes them valuable for use in therapeutic treatment. The invention also relates to a method of obtaining IGF-I as defined above by expressing IGF-I in yeast cells and isolating the claimed O-glycosylated IGF-I from the medium and to pharmaceutical composition containing these IGF-I together with a pharmaceutically acceptable carrier, diluent or excipient. It also relates to the use of the O-glycosylated IGF-I in the preparation of a medicament for the treatment of e.g. growth deficiency and insulin resistant states.
SE9402332A 1994-07-01 1994-07-01 IGF-1 SE9402332D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE9402332A SE9402332D0 (en) 1994-07-01 1994-07-01 IGF-1
IL11427095A IL114270A0 (en) 1994-07-01 1995-06-22 O-glycosylated authentic igf-i and truncated variants thereof a method of preparation thereof and pharmaceutical compositions
CA002193399A CA2193399A1 (en) 1994-07-01 1995-06-22 O-glycosylated authentic igf-i and truncated variants thereof, a method of preparation thereof and pharmaceutical compositions
EP95925201A EP0769022A1 (en) 1994-07-01 1995-06-22 O-glycosylated authentic igf-i and truncated variants thereof, a method of preparation thereof and pharmaceutical compositions
AU29406/95A AU2940695A (en) 1994-07-01 1995-06-22 O-glycosylated authentic igf-i and truncated variants thereof, a method of preparation thereof and pharmaceutical compositions
PCT/SE1995/000774 WO1996001275A1 (en) 1994-07-01 1995-06-22 O-glycosylated authentic igf-i and truncated variants thereof, a method of preparation thereof and pharmaceutical compositions
JP8503823A JPH10502623A (en) 1994-07-01 1995-06-22 O-glycosylated authentic IGF-I and truncated variants thereof, methods for their preparation, and pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402332A SE9402332D0 (en) 1994-07-01 1994-07-01 IGF-1

Publications (1)

Publication Number Publication Date
SE9402332D0 true SE9402332D0 (en) 1994-07-01

Family

ID=20394599

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9402332A SE9402332D0 (en) 1994-07-01 1994-07-01 IGF-1

Country Status (7)

Country Link
EP (1) EP0769022A1 (en)
JP (1) JPH10502623A (en)
AU (1) AU2940695A (en)
CA (1) CA2193399A1 (en)
IL (1) IL114270A0 (en)
SE (1) SE9402332D0 (en)
WO (1) WO1996001275A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501472D0 (en) * 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
SE9802938D0 (en) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
HUE027645T2 (en) 2005-01-07 2016-10-28 Regeneron Pharma IGF-1 fusion polypeptides and therapeutic uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
DK0597033T3 (en) * 1991-08-01 1997-06-02 Genentech Inc IGF-1 to improve the neural state

Also Published As

Publication number Publication date
WO1996001275A1 (en) 1996-01-18
EP0769022A1 (en) 1997-04-23
CA2193399A1 (en) 1996-01-18
IL114270A0 (en) 1995-10-31
JPH10502623A (en) 1998-03-10
AU2940695A (en) 1996-01-25

Similar Documents

Publication Publication Date Title
CA2223433A1 (en) Ob protein compositions and methods
ATE316100T1 (en) EXENDIN ANALOGAS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING SAME
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
EP1175909A8 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
WO2002020766A3 (en) G-csf analog compositions and methods
DE69840909D1 (en) ANALOG OF COCAINE
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
MY135057A (en) Dolastatin 15 derivatives
ATE85345T1 (en) NEW CADIODILATIN FRAGMENT, PROCESS FOR ITS PRODUCTION AND ITS APPLICATION.
ATE211391T1 (en) USE OF HMG PROTEINS FOR THE PRODUCTION OF MEDICINAL PRODUCTS WITH CYTOTOXIC ACTION
SE9501472D0 (en) Truncated IGF-I
EP1080724A4 (en) Mtp activity-lowering compositions
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
WO1996025498A3 (en) Mpl ligand analogs
KR970701724A (en) Corpuscles of stannius protein (stanniocalcin)
SE9402332D0 (en) IGF-1
WO2001083722A3 (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
AU7526196A (en) Molecular cloning and characterization of molecules related to relaxin and the insulin family of ligands
AU2806597A (en) Human DNase II
DE69420574D1 (en) DERIVATIVES OF THERAPEUTICALLY EFFECTIVE PEPTIDES IN THE BLOOD COLLECTING CASCADE, METHOD FOR THE PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
EP0832109A4 (en) Fibroblast growth factor homologous factor-2 and methods of use
UA66749C2 (en) Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases
WO2002012336A3 (en) TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
WO2004058811A3 (en) Crystal structures of yhhf polypeptides